The latest advance for developing CRISPR, using the powerful genome-editing technique, involves using the technology to build chimeric antigen receptor (CAR) T cells, a type of immunotherapy for cancer.
In a new study published in the journal Nature, Memorial Sloan Kettering Cancer Center’s Michel Sadelain and colleagues show how CRISPR can be used to create CAR T cells with improved performance — packing more punch against tumors in mice.
